Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;106:2397-2403
Published online before print October 14, 2002, doi: 10.1161/01.CIR.0000034733.93020.BC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/18/2397    most recent
01.CIR.0000034733.93020.BCv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yokoyama, C.
Right arrow Articles by Tanabe, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokoyama, C.
Right arrow Articles by Tanabe, T.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Genetically altered mice

(Circulation. 2002;106:2397.)
© 2002 American Heart Association, Inc.


Basic Science Reports

Prostacyclin-Deficient Mice Develop Ischemic Renal Disorders, Including Nephrosclerosis and Renal Infarction

Chieko Yokoyama, PhD; Tomoko Yabuki, PhD; Manabu Shimonishi, PhD; Masayuki Wada, MSc; Toshihisa Hatae, PhD; Susumu Ohkawara, PhD; Junji Takeda, MD, PhD; Taroh Kinoshita, PhD; Masaru Okabe, PhD; Tadashi Tanabe, PhD

From the Department of Pharmacology, National Cardiovascular Center Research Institute (C.Y., T.Y., M.S., M.W., T.H., S.O., T.T.), Division of Microcirculatory Kinetics (M.W., T.T.), and Department of Social and Environmental Medicine (J.T.), Graduate School of Medicine, Research Institute for Microbial Diseases (T.K.), and Genome Information Research Center (M.O.), Osaka University, Suita, Osaka, Japan.

Correspondence to Tadashi Tanabe, PhD, Department of Pharmacology, National Cardiovascular Center Research Institute, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. E-mail tanabe{at}kiko.go.jp

Background— Prostacyclin (PGI2) is a short-lived endogenous inhibitor of platelet aggregation and a potent vasodilator and regulator of the growth of vascular smooth muscle cells. To study the role of PGI2 in the vascular system in vivo, PGI2-deficient (PGID) mice were established by genetic disruption of the PGI2 synthase gene.

Methods and Results— PGI2 synthase–null mice were generated by replacing the exons of PGI2 synthase gene that encodes for the catalytic site of the enzyme with a neomycin resistance gene. In these mice, PGI2 levels in the plasma, kidneys, and lungs were reduced, whereas thromboxane and prostaglandin E2 levels became elevated. Blood pressure and the amounts of urea nitrogen and creatinine in plasma of the PGID mice were significantly higher than those of wild-type mice (P<0.05). They developed progressive morphological abnormalities in the kidneys, accompanied by atrophy, surface irregularity, fibrosis, cyst, arterial sclerosis, and hypertrophy of vessel walls. Thickening of the thoracic aortic media and adventitia were observed in aged PGID mice. Importantly, these phenotypes have not been reported in PGI2 receptor–deficient mice.

Conclusions— PGI2 deficiency resulted in the development of vascular disorders with the thickening of vascular walls and interstitial fibrosis, especially in mouse kidneys. The findings demonstrated in vivo that PGI2 is important in the homeostasis of blood vessels. Our established PGID mice are useful for studies on the initiation and development of vascular diseases, such as ischemic renal disorders with arterial sclerosis and infarction, and also for studies on the novel signaling pathway of PGI2.


Key Words: prostaglandins • thromboxane • kidney • arteriosclerosis • hypertension




This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
H. Francois, C. Facemire, A. Kumar, L. Audoly, B. Koller, and T. Coffman
Role of Microsomal Prostaglandin E Synthase 1 in the Kidney
J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1466 - 1475.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Zhang, Z. Dong, and T. Yang
Prostaglandin D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in MDCK cells
Am J Physiol Renal Physiol, December 1, 2006; 291(6): F1332 - F1342.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Ohashi, S. Kihara, N. Ouchi, M. Kumada, K. Fujita, A. Hiuge, T. Hibuse, M. Ryo, H. Nishizawa, N. Maeda, et al.
Adiponectin Replenishment Ameliorates Obesity-Related Hypertension
Hypertension, June 1, 2006; 47(6): 1108 - 1116.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Chi, S. M. Khersonsky, Y.-T. Chang, and V. L. Schuster
Identification of a New Class of Prostaglandin Transporter Inhibitors and Characterization of Their Biological Effects on Prostaglandin E2 Transport
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1346 - 1350.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
E. Fosslien
Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs
Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Nasrallah and R. L. Hebert
Prostacyclin signaling in the kidney: implications for health and disease
Am J Physiol Renal Physiol, August 1, 2005; 289(2): F235 - F246.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Hara, K.-i. Yuhki, T. Fujino, T. Yamada, K. Takayama, S. Kuriyama, O. Takahata, H. Karibe, Y. Okada, C.-Y. Xiao, et al.
Augmented Cardiac Hypertrophy in Response to Pressure Overload in Mice Lacking the Prostaglandin I2 Receptor
Circulation, July 5, 2005; 112(1): 84 - 92.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. E. Trebino, J. D. Eskra, T. S. Wachtmann, J. R. Perez, T. J. Carty, and L. P. Audoly
Redirection of Eicosanoid Metabolism in mPGES-1-deficient Macrophages
J. Biol. Chem., April 29, 2005; 280(17): 16579 - 16585.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J.-C. Huang, W.-S.A. Wun, J. S. Goldsby, N. Matijevic-Aleksic, and K. K. Wu
Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatching
Hum. Reprod., December 1, 2004; 19(12): 2900 - 2906.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. H. Ritchie, A. C. Rosenkranz, L. P. Huynh, T. Stephenson, D. M. Kaye, and G. J. Dusting
Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1179 - H1185.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Boulet, M. Ouellet, K. P. Bateman, D. Ethier, M. D. Percival, D. Riendeau, J. A. Mancini, and N. Methot
Deletion of Microsomal Prostaglandin E2 (PGE2) Synthase-1 Reduces Inducible and Basal PGE2 Production and Alters the Gastric Prostanoid Profile
J. Biol. Chem., May 28, 2004; 279(22): 23229 - 23237.
[Abstract] [Full Text] [PDF]